Published in J Natl Cancer Inst on June 06, 2001
When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer (2009) 5.86
Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03
Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med (2008) 2.74
Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J Natl Cancer Inst (2009) 2.57
The Human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection. Genome Res (2004) 2.54
Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer. Br J Cancer (2011) 1.73
Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer (2006) 1.66
Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer (2004) 1.48
Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS One (2010) 1.40
Translational genomics: the challenge of developing cancer biomarkers. Genome Res (2012) 1.26
Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig Dis Sci (2007) 1.19
Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer. J Gastroenterol (2011) 1.16
Enhanced retrieval of DNA from human fecal samples results in improved performance of colorectal cancer screening test. J Mol Diagn (2004) 1.11
Promoter hypermethylation of tumour suppressor genes as potential biomarkers in colorectal cancer. Int J Mol Sci (2015) 1.09
Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK. World J Gastroenterol (2006) 1.09
Long-range epigenetic silencing at 2q14.2 affects most human colorectal cancers and may have application as a non-invasive biomarker of disease. Br J Cancer (2009) 1.08
Primary and secondary prevention of colorectal cancer. Clin Med Insights Gastroenterol (2014) 1.07
The Diagnostic and Prognostic Role of microRNA in Colorectal Cancer - a Comprehensive review. J Cancer (2013) 1.05
Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries. BMC Cancer (2006) 1.04
Sensitive and specific detection of K-ras mutations in colon tumors by short oligonucleotide mass analysis. Nucleic Acids Res (2004) 0.99
Kallikrein 6 is a mediator of K-RAS-dependent migration of colon carcinoma cells. Biol Chem (2008) 0.96
Stool-based DNA testing, a new noninvasive method for colorectal cancer screening, the first report from Iran. World J Gastroenterol (2007) 0.95
High sensitivity EndoV mutation scanning through real-time ligase proofreading. Nucleic Acids Res (2004) 0.94
Biomarkers of coordinate metabolic reprogramming in colorectal tumors in mice and humans. Gastroenterology (2014) 0.93
Early detection of colorectal cancer: from conventional methods to novel biomarkers. J Cancer Res Clin Oncol (2015) 0.92
GNAS sequencing identifies IPMN-specific mutations in a subgroup of diminutive pancreatic cysts referred to as "incipient IPMNs". Am J Surg Pathol (2014) 0.92
Colorectal cancer biomarkers and the potential role of cancer stem cells. J Cancer (2013) 0.92
Multi-target stool DNA test: a new high bar for noninvasive screening. Dig Dis Sci (2014) 0.91
GNAS codon 201 mutations are uncommon in intraductal papillary neoplasms of the bile duct. HPB (Oxford) (2012) 0.91
DPEP1, expressed in the early stages of colon carcinogenesis, affects cancer cell invasiveness. J Gastroenterol (2010) 0.88
An update on microRNAs as colorectal cancer biomarkers: where are we and what's next? Expert Rev Mol Diagn (2014) 0.87
Implications of new colorectal cancer screening technologies for primary care practice. Med Care (2008) 0.87
Cost-effectiveness of colorectal cancer screening in the average risk population. Health Care Manag Sci (2003) 0.85
MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of colorectal cancer. Int J Med Sci (2011) 0.85
From the genome to the proteome--biomarkers in colorectal cancer. Langenbecks Arch Surg (2007) 0.84
Detection of hypermethylated vimentin in urine of patients with colorectal cancer. J Mol Diagn (2012) 0.84
Improved recovery of exfoliated colonocytes from feces using newly developed immunomagnetic beads. Gastroenterol Res Pract (2008) 0.83
Usefulness of fecal lactoferrin and hemoglobin in diagnosis of colorectal diseases. World J Gastroenterol (2007) 0.83
PCR/LDR/universal array platforms for the diagnosis of infectious disease. Methods Mol Biol (2010) 0.82
Evidence-based Guidelines for Precision Risk Stratification-Based Screening (PRSBS) for Colorectal Cancer: Lessons learned from the US Armed Forces: Consensus and Future Directions. J Cancer (2013) 0.82
Fecal molecular markers for colorectal cancer screening. Gastroenterol Res Pract (2011) 0.82
Prognostic value of postoperative detection of blood circulating tumor cells in patients with colorectal cancer operated on for cure. Ann Surg (2003) 0.81
Cell-free nucleic acids as noninvasive biomarkers for colorectal cancer detection. Front Genet (2014) 0.80
Screening for colon cancer. Cancer Imaging (2006) 0.79
Detection of BRAF mutations in colorectal tumours and peritoneal washings using a mismatch ligation assay. J Clin Pathol (2005) 0.79
Stool DNA-based colorectal cancer detection: finding the needle in the haystack. J Natl Cancer Inst (2001) 0.79
BRAF, K-ras and BAT26 mutations in colorectal polyps and stool. World J Gastroenterol (2006) 0.79
Detection of colorectal cancer by a quantitative fluorescence determination of DNA amplification in stool. Neoplasia (2004) 0.79
Elimination of unaltered DNA in mixed clinical samples via nuclease-assisted minor-allele enrichment. Nucleic Acids Res (2016) 0.77
Detecting K-ras mutations in stool from fecal occult blood test cards in multiphasic screening for colorectal cancer. Cancer Lett (2007) 0.76
Genetic and epigenetic marker-based DNA test of stool is a promising approach for colorectal cancer screening. Yonsei Med J (2009) 0.76
Highly sensitive, non-invasive detection of colorectal cancer mutations using single molecule, third generation sequencing. Appl Transl Genom (2015) 0.75
Predictive Levels of CD24 in Peripheral Blood Leukocytes for the Early Detection of Colorectal Adenomas and Adenocarcinomas. Dis Markers (2015) 0.75
Fecal DNA-Based Detection of Colorectal Neoplasia. Curr Colorectal Cancer Rep (2007) 0.75
Analysis of microsatellite instability in stool DNA of patients with colorectal cancer using denaturing high performance liquid chromatography. World J Gastroenterol (2006) 0.75
Colorectal Cancer Screening: Stool DNA and Other Noninvasive Modalities. Gut Liver (2016) 0.75
Clinical implications of new information on colorectal cancer genes. Rev Gastroenterol Disord (2002) 0.75
Is stool DNA multitarget testing an unreliable strategy for colorectal cancer screening? Gut (2005) 0.75
Detection of fecal interferon-induced transmembrane protein messenger RNA for colorectal cancer screening. Oncol Lett (2010) 0.75
Long-fragment DNA as a potential marker for stool-based detection of colorectal cancer. Oncol Lett (2014) 0.75
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem (1983) 206.01
"A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity". Addendum. Anal Biochem (1984) 66.58
Serial analysis of gene expression. Science (1995) 60.15
A genetic model for colorectal tumorigenesis. Cell (1990) 44.37
WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 38.72
Surfing the p53 network. Nature (2000) 35.36
p53 mutations in human cancers. Science (1991) 31.96
Preparative and analytical purification of DNA from agarose. Proc Natl Acad Sci U S A (1979) 27.20
Genetic alterations during colorectal-tumor development. N Engl J Med (1988) 26.82
Lessons from hereditary colorectal cancer. Cell (1996) 25.73
Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science (1997) 24.61
A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A (1998) 24.58
Identification of c-MYC as a target of the APC pathway. Science (1998) 24.25
Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science (1997) 22.80
Genetic instabilities in human cancers. Nature (1998) 22.76
A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell (1992) 19.87
Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science (1998) 17.91
Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (1992) 17.40
Participation of p53 protein in the cellular response to DNA damage. Cancer Res (1991) 16.00
Clues to the pathogenesis of familial colorectal cancer. Science (1993) 14.52
Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst (2000) 14.43
Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science (1995) 13.15
Definition of a consensus binding site for p53. Nat Genet (1992) 12.76
Genetic instability in colorectal cancers. Nature (1997) 12.51
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med (2000) 12.34
Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science (1989) 11.53
Identification of FAP locus genes from chromosome 5q21. Science (1991) 11.41
A model for p53-induced apoptosis. Nature (1997) 11.38
Characterization of the yeast transcriptome. Cell (1997) 11.33
Mutations of mitotic checkpoint genes in human cancers. Nature (1998) 11.20
Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (1990) 11.18
Genes expressed in human tumor endothelium. Science (2000) 10.75
Digital PCR. Proc Natl Acad Sci U S A (1999) 10.54
Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science (1992) 10.12
Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell (1993) 9.93
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A (1998) 9.66
Gene expression profiles in normal and cancer cells. Science (1997) 9.65
APC mutations occur early during colorectal tumorigenesis. Nature (1992) 9.50
Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature (1983) 9.28
Prevalence of ras gene mutations in human colorectal cancers. Nature (1987) 9.23
5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med (1995) 9.10
A public database for gene expression in human cancers. Cancer Res (1999) 8.81
Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet (1994) 8.34
Identification of a chromosome 18q gene that is altered in colorectal cancers. Science (1990) 8.32
Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol (1983) 8.24
PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell (2001) 7.95
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature (1993) 7.90
p53 function and dysfunction. Cell (1992) 7.73
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med (2000) 7.54
Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res (1995) 7.42
Head and neck cancer. N Engl J Med (2001) 7.32
14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell (1997) 7.20
Association of the APC tumor suppressor protein with catenins. Science (1993) 7.17
Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A (1987) 7.12
A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med (2001) 7.07
Oncogenic forms of p53 inhibit p53-regulated gene expression. Science (1992) 6.73
p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res (1995) 6.66
The molecular basis of Turcot's syndrome. N Engl J Med (1995) 6.65
Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell (1993) 6.61